ArticleGut2012
Statin use and the risk of Clostridium difficile in academic medical centres.
Article in Gut, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Statins & risk ofThe Indian journal of medical research · 2019Pooled it
- Rosuvastatin alters the genetic composition of the human gut microbiome.Scientific reports · 2020Trial
- Association between statin administration andFrontiers in pharmacology · 2025Article
- Unveiling the Antibacterial Properties of Statins: AnAdvances in pharmacological and pharmaceutical sciences · 2024Article
- Article
- Role of the gut microbiome in cardiovascular drug response: The potential for clinical application.Pharmacotherapy · 2022Review
- Gut CommensalFrontiers in immunology · 2022Article
- Article
- Review
- Article
- Membrane Cholesterol Is Crucial forFrontiers in immunology · 2020Article
- Article
- Statin Use and the Point Prevalence of Antibiotics in Ambulatory Patients with Diabetes in the National Health and Nutrition Examination Survey (NHANES) 2003-2012.Antibiotics (Basel, Switzerland) · 2019Article
- Predictors of Clostridium difficile infection and predictive impact of probiotic use in a diverse hospital-wide cohort.American journal of infection control · 2019Article
- Meta-analysis comparing the effects of statins on the risk ofProceedings (Baylor University. Medical Center) · 2018Article
- Treatment with Atorvastatin Provides Additional Benefits to Imipenem in a Model of Gram-Negative Pneumonia Induced by Klebsiella pneumoniae in Mice.Antimicrobial agents and chemotherapy · 2018Article
- Statin use and the risk ofInfection and drug resistance · 2018Review
- Overexpression of the Endosomal Anion/Proton Exchanger ClC-5 Increases Cell Susceptibility towardFrontiers in cellular and infection microbiology · 2017Article
- The Association between GABA-Modulators and Clostridium difficile Infection - A Matched Retrospective Case-Control Study.PloS one · 2017Article
- Analysis of the Impact of Rosuvastatin on Bacterial Mevalonate Production Using a UPLC-Mass Spectrometry Approach.Current microbiology · 2016Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesTo estimate the possible relationship between statin use and the risk of healthcare facility onset Clostridium difficile.
methodsPatients over 18 years of age admitted to hospitals contributing data to the University HealthSystem Consortium between 2002 and 2009 were eligible. Patients with the ICD-9-CM code 008.45 who received a minimum 3-day course of either metronidazole or oral vancomycin on/after day 5 of admission were considered incident cases of C difficile infection. 31,472 incident cases of C difficile infection were identified and matched to five controls, on hospital, year/quarter of admission date, and age ±10 years (N=78,096). Patients who were administered one drug in the statin class (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin or simvastatin) before the index date were considered to be exposed. Conditional logistic regression modelling provided adjusted odds ratios and 95% CI.
resultsCompared with non-users, users of any drug within the statin class were 0.78 times less likely to develop C difficile infection in the hospital (95% CI 0.75 to 0.81) adjusting for potential confounders. Differences in estimates for specific statins were minimal. Niacin, fibrates and selective cholesterol absorption inhibitors showed no association with the risk of C difficile infection.
conclusionsOur data were consistent with a growing body of literature demonstrating a reduced risk of infections with statin use. Statins' pleiotropic properties may provide protection against C difficile infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.